{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T08:27:43Z","timestamp":1743496063481},"reference-count":27,"publisher":"Japan Atherosclerosis Society","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Atheroscler Thromb","JAT"],"published-print":{"date-parts":[[2015]]},"DOI":"10.5551\/jat.28175","type":"journal-article","created":{"date-parts":[[2015,1,15]],"date-time":"2015-01-15T22:09:38Z","timestamp":1421359778000},"page":"660-668","source":"Crossref","is-referenced-by-count":5,"title":["Fluvastatin Upregulates the Expression of Tissue Factor Pathway Inhibitor in Human Umbilical Vein Endothelial Cells"],"prefix":"10.5551","volume":"22","author":[{"given":"Akiko","family":"Sekiya","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory Science, Kanazawa University Graduate School of Medical Science"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eriko","family":"Morishita","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Science, Kanazawa University Graduate School of Medical Science"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Maruyama","sequence":"additional","affiliation":[{"name":"National Cerebral and Cardiovascular Center, Department of Molecular Pathogenesis"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Torishima","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Science, Kanazawa University Graduate School of Medical Science"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Ohtake","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Science, Kanazawa University Graduate School of Medical Science"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Winckers K, ten Cate H, Hackeng TM: The role of tissue factor pathway inhibitor in atherosclerosis and arterial thrombosis. Blood Rev, 2013; 27: 119-132","DOI":"10.1016\/j.blre.2013.03.001"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Zhang J, Piro O, Lu L, Broze GJ Jr: Glycosyl phosphatidylinositol anchorage of tissue factor pathway inhibitor. Circulation, 2003; 108: 623-627","DOI":"10.1161\/01.CIR.0000078642.45127.7B"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Maroney SA, Ellery PE, Wood JP, Ferrel JP, Martinez ND, Mast AE: Comparison of the inhibitory activities of human tissue factor pathway inhibitor (TFPI)\u03b1 and TFPI\u03b2. J Thromb Haemost, 2013; 11: 911-918","DOI":"10.1111\/jth.12188"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Takemoto M, Liao JK: Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol, 2001; 21: 1712-1719","DOI":"10.1161\/hq1101.098486"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Undas A, Brummel-Ziedins KE, Mann KG: Anticoagulant effects of statins and their clinical implications. Thromb Haemost, 2014; 111: 392-400","DOI":"10.1160\/TH13-08-0720"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Masamura K, Oida K, Kanehara H, Suzuki J, Horie S, Ishii H, Miyamori I: Pitavastatin-induced thrombomodu lin expression by endothelial cells acts via inhibition of small G proteins of the Rho family. Arterioscler Thromb Vasc Biol, 2003; 23: 512-517","DOI":"10.1161\/01.ATV.0000060461.64771.F0"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Yamazaki K, Morishita E, Hirano K, Sekino T, Yoshida T, Hayashi T, Ontachi Y, Yamazaki M, Asakura H, Nakao S, Ohtake S: Effects of HMG-CoA reductase inhibitors on blood coagulation and fibrinolytic regulation factors in the endothelial cell. Jpn J Thromb Hemost, 2006; 17: 454-461","DOI":"10.2491\/jjsth.17.454"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Eto M, Kozai T, Cosentino F, Joch H, L\u00fcscher TF: Statin prevents tissue factor expression in human endothelial cells: role of Rho\/Rho-kinase and Akt pathways. Circulation, 2002; 105: 1756-1759","DOI":"10.1161\/01.CIR.0000015465.73933.3B"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Morishita E, Asakura H, Saito M, Yamazaki M, Ontachi Y, Mizutani T, Kato M, Matsuda T, Nakao S: Elevated plasma levels of free-form of TFPI antigen in hypercholesterolemic patients. Atherosclerosis, 2001; 154: 203-212","DOI":"10.1016\/S0021-9150(00)00463-9"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Hansen JB, Huseby NE, Sandset PM, Svensson B, Lyngmo V, Nord\u00f8y A: Tissue-factor pathway inhibitor and lipoproteins. Evidence for association with and regulation by LDL in human plasma. Arterioscler Thromb, 1994; 14: 223-229","DOI":"10.1161\/01.ATV.14.2.223"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Atalar E, Coskun S, Haznedaroglu IC, Y\u00fccel N, Ozer N, Sivri B, Aksoyek S, Ovunc K, Ozmen F: Immediate effects of fluvastain on circulating soluble endothelial protein C and free tissue factor pathway inhibitor in acute coronary syndromes. Cardiovasc Drugs Ther, 2005; 19: 177-181","DOI":"10.1007\/s10557-005-2160-x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Petit L, Lesnik P, Dachet C, Hugou I, Moreau M, Chapman J, Rouis M: The promoter of human tissue factor pathway inhibitor gene: identification of potential regulatory elements. Thromb Res, 1999; 95: 255-262","DOI":"10.1016\/S0049-3848(99)00040-7"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Morishita R, Tomita N, Ogihara T: HMG-Co A reductase inhibitors in the treatment of cardiovascular diseases: stabilization of coronary artery plaque. Curr Drug Targets, 2002; 3: 379-385","DOI":"10.2174\/1389450023347434"},{"key":"14","unstructured":"14) Bellosta S, Ferri N, Arnaboldi L, Bernini F, Paoletti R, Corsini A: Pleiotropic effects of statins in atherosclerosis and diabetes. Diabetes Care, 2000; 23 Suppl 2: B72-78"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Hinkelmann U, Grosser N, Erdmann K, Schr\u00f6der H, Immenschuh S: Simvastatin-dependent up-regulation of heme oxygenase-1 via mRNA stabilization in human endothelial cells. Eur J Pharm Sci, 2010; 41: 118-124","DOI":"10.1016\/j.ejps.2010.05.021"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Chang HL, Chen CY, Hsu YF, Kuo WS, Ou G, Chiu PT, Huang YH, Hsu MJ: Simvastatin induced HCT116 colorectal cancer cell apoptosis through p38MAPK-p53-survivin signaling cascade. Biochim Biophys Acta, 2013; 1830: 4053-4064","DOI":"10.1016\/j.bbagen.2013.04.011"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Gao P, Wu X, Shui H, Jia R: Fluvastatin inhibits angiotensin II-induced nuclear factor kappa B activation in renal tubular epithelial cells through the p38 MAPK pathway. Mol Biol Rep, 2012; 39: 4719-4725","DOI":"10.1007\/s11033-011-1264-6"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Bao XM, Wu CF, Lu GP: Atorvastatin inhibits homocysteine-induced oxidative stress and apoptosis in endothelial progenitor cells involving Nox4 and p38MAPK. Atherosclerosis, 2010; 210: 114-121","DOI":"10.1016\/j.atherosclerosis.2009.11.032"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, Walsh K: The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med, 2000; 6: 1004-1010","DOI":"10.1038\/79510"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Skaletz-Rorowski A, Lutchman M, Kureishi Y, Lefer DJ, Faust JR, Walsh K: HMG-CoA reductase inhibitors promote cholesterol-dependent Akt\/PKB translocation to membrane domains in endothelial cells. Cardiovasc Res, 2003; 57: 253-264","DOI":"10.1016\/S0008-6363(02)00618-1"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Makabe S, Takahashi Y, Watanabe H, Murakami M, Ohba T, Ito H: Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway. Atherosclerosis, 2010; 213: 377-384","DOI":"10.1016\/j.atherosclerosis.2010.07.059"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Petit L, Lesnik P, Dachet C, Hugou I, Moreau M, Chapman J, Rouis M: The promoter of human tissue factor pathway inhibitor gene: identification of potential regulatory elements. Thromb Res, 1999; 95: 255-262","DOI":"10.1016\/S0049-3848(99)00040-7"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Habara K, Hamada Y, Yamada M, Tokuhara K, Tanaka H, Kaibori M, Kamiyama Y, Nishizawa M, Ito S, Okumura T: Pitavastatin up-regulates the induction of iNOS through enhanced stabilization of its mRNA in pro-inflammatory cytokine-stimulated hepatocytes. Nitric Oxide, 2008; 18: 19-27","DOI":"10.1016\/j.niox.2007.08.005"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Ellery PE, Maroney SA, Martinez ND, Wickens MP, Mast AE: Translation of human tissue factor pathway inhibitor-b mRNA is controlled by alternative splicing within the 5' untranslated region. Arterioscler Thromb Vasc Biol, 2014; 34: 187-195","DOI":"10.1161\/ATVBAHA.113.302660"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Eberhardt W, Doller A, Akool el-S, Pfeilschifter J: Modulation of mRNA stability as a novel therapeutic approach. Pharmacol Ther, 2007; 114: 56-73","DOI":"10.1016\/j.pharmthera.2007.01.002"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, Light B, Spapen H, Stone J, Seibert A, Peckelsen C, De Deyne C, Postier R, Pettil\u00e4 V, Artigas A, Percell SR, Shu V, Zwingelstein C, Tobias J, Poole L, Stolzenbach JC, Creasey AA; OPTIMIST Trial Study Group: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA, 2003; 290: 238-247","DOI":"10.1001\/jama.290.2.238"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Wunderink RG, Laterre PF, Francois B, Perrotin D, Artigas A, Vidal LO, Lobo SM, Juan JS, Hwang SC, Dugernier T, LaRosa S, Wittebole X, Dhainaut JF, Doig C, Mendelson MH, Zwingelstein C, Su G, Opal S; CAPTIVATE Trial Group: Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med, 2011; 183: 1561-1568","DOI":"10.1164\/rccm.201007-1167OC"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/22\/7\/22_28175\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T19:23:37Z","timestamp":1566242617000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/22\/7\/22_28175\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.28175","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}